• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从NCB 20细胞中溶解出来的5-羟色胺3型受体的分子大小。

Molecular size of the 5-HT3 receptor solubilized from NCB 20 cells.

作者信息

McKernan R M, Biggs C S, Gillard N, Quirk K, Ragan C I

机构信息

Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, U.K.

出版信息

Biochem J. 1990 Aug 1;269(3):623-8. doi: 10.1042/bj2690623.

DOI:10.1042/bj2690623
PMID:2390056
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1131632/
Abstract

The 5-HT3 hydroxytryptamine receptor from NCB 20 cells was solubilized and the molecular and hydrodynamic properties of the receptor were investigated. The receptor was identified by binding of the radioligand 3-NN'-[3H]dimethyl-8-azabicyclo[3.2.1]octanyl indol-3-yl carboxylate ester [( 3H]Q ICS 205-930) to NCB 20 membranes (Bmax = 1.19 +/- 0.31 pmol/mg of protein; Kd = 0.43 +/- 0.076 nM) and was optimally solubilized with 0.5% deoxycholate. [3H]Q ICS 205-930 labelled one population of sites in solution (Bmax = 1.11 +/- 0.4 pmol/mg of protein; Kd = 0.48 +/- 0.06 nM; n = 4). The characteristics of [3H]Q ICS 205-930 binding were essentially unchanged by solubilization, and competition for [3H]Q ICS 205-930 binding by a series of 5-HT3 agonists and antagonists was consistent with binding to a 5-HT3 receptor site and was similar to that observed for 5-HT3 receptors solubilized from rat brain [McKernan, Quirk, Jackson & Ragan (1990) J. Neurochem. 54, 924-930]. Some physical properties of the solubilized receptor were investigated. The molecular size (Stokes radius) of the [3H]Q ICS 205-930-binding site was measured by gel-exclusion chromatography in a buffer containing 0.2% Lubrol and 0.5 M-NaCl and was determined as 4.81 +/- 0.15 nm (mean +/- S.E.M.; n = 6). Sucrose-density-gradient centrifugation was also performed under the same detergent and salt conditions to determine the partial specific volume (v) of the detergent-receptor site complex. This was found to be 0.794 ml.g-1. Sucrose-density-gradient centrifugation was carried out in both 1H2O and 2H2O to allow correction for detergent binding to the receptor. The Mr of the 5-HT3 receptor under these conditions was calculated as 249,000 +/- 18,000 (n = 3). The size and physical properties of the 5-HT3 receptor are similar to those observed for members of the family of ligand-gated ion channels.

摘要

从NCB 20细胞中溶解5-羟色胺3(5-HT3)受体,并对该受体的分子和流体动力学性质进行了研究。通过放射性配体3-NN'-[3H]二甲基-8-氮杂双环[3.2.1]辛基吲哚-3-基羧酸酯[(3H]Q ICS 205-930)与NCB 20细胞膜的结合来鉴定该受体(Bmax = 1.19±0.31 pmol/mg蛋白质;Kd = 0.43±0.076 nM),并用0.5%脱氧胆酸盐将其最佳溶解。[3H]Q ICS 205-930在溶液中标记了一组位点(Bmax = 1.11±0.4 pmol/mg蛋白质;Kd = 0.48±0.06 nM;n = 4)。溶解后,[3H]Q ICS 205-930结合的特性基本不变,一系列5-HT3激动剂和拮抗剂对[3H]Q ICS 205-930结合的竞争与与5-HT3受体位点的结合一致,并且与从大鼠脑溶解的5-HT3受体观察到的情况相似[麦肯南、夸克、杰克逊和拉根(1990年)《神经化学杂志》54,924 - 930]。研究了溶解受体的一些物理性质。在含有0.2%十二烷基醇聚氧乙烯醚和0.5 M氯化钠的缓冲液中,通过凝胶排阻色谱法测量[3H]Q ICS 205-930结合位点的分子大小(斯托克斯半径),确定为4.81±0.15 nm(平均值±标准误;n = 6)。在相同的去污剂和盐条件下也进行了蔗糖密度梯度离心,以确定去污剂-受体位点复合物的偏比容(v)。发现其为0.794 ml·g-1。在1H2O和2H2O中都进行了蔗糖密度梯度离心,以便校正去污剂与受体的结合。在这些条件下,5-HT3受体的Mr计算为249,000±18,000(n = 3)。5-HT3受体的大小和物理性质与配体门控离子通道家族成员观察到的相似。

相似文献

1
Molecular size of the 5-HT3 receptor solubilized from NCB 20 cells.从NCB 20细胞中溶解出来的5-羟色胺3型受体的分子大小。
Biochem J. 1990 Aug 1;269(3):623-8. doi: 10.1042/bj2690623.
2
Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.使用[3H]-喹哌嗪和[3H]-GR65630结合法研究NG108-15、NCB-20神经母细胞瘤细胞及大鼠大脑皮层中5-HT3结合位点的特征
Br J Pharmacol. 1991 Apr;102(4):919-25. doi: 10.1111/j.1476-5381.1991.tb12277.x.
3
Purification of the 5-hydroxytryptamine 5-HT3 receptor from NCB20 cells.从NCB20细胞中纯化5-羟色胺5-HT3受体。
J Biol Chem. 1990 Aug 15;265(23):13572-7.
4
Physicochemical properties of serotonin 5-HT3 binding sites solubilized from membranes of NG 108-15 neuroblastoma-glioma cells.从NG 108-15神经母细胞瘤-胶质瘤细胞膜中溶解出来的5-羟色胺5-HT3结合位点的物理化学性质。
J Neurochem. 1990 Nov;55(5):1526-36. doi: 10.1111/j.1471-4159.1990.tb04935.x.
5
Competitive interaction of agonists and antagonists with 5-HT3 recognition sites in membranes of neuroblastoma cells labelled with [3H]ICS 205-930.激动剂和拮抗剂与用[3H]ICS 205-930标记的神经母细胞瘤细胞膜中5-HT3识别位点的竞争性相互作用。
J Recept Res. 1989;9(1):65-79. doi: 10.3109/10799898909066045.
6
Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding.通过放射性配体结合鉴定N1E-115神经母细胞瘤细胞膜中的5-羟色胺5-HT3识别位点。
Mol Pharmacol. 1988 Mar;33(3):303-9.
7
Solubilisation of the 5-hydroxytryptamine3 receptor from pooled rat cortical and hippocampal membranes.从大鼠皮层和海马膜匀浆中溶解5-羟色胺3受体。
J Neurochem. 1990 Mar;54(3):924-30. doi: 10.1111/j.1471-4159.1990.tb02339.x.
8
Purification of 5-hydroxytryptamine3 receptors from porcine brain.从猪脑中纯化5-羟色胺3受体。
Br J Pharmacol. 1997 Oct;122(4):655-62. doi: 10.1038/sj.bjp.0701439.
9
Characterisation of 5-HT3 recognition sites in membranes of NG 108-15 neuroblastoma-glioma cells with [3H]ICS 205-930.用[³H]ICS 205-930对NG 108-15神经母细胞瘤-胶质瘤细胞膜中5-HT3识别位点的表征。
Naunyn Schmiedebergs Arch Pharmacol. 1988 May;337(5):493-9. doi: 10.1007/BF00182721.
10
Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron.与[3H] - 格拉司琼相比,非典型5 - HT3受体配体[3H] - BRL46470标记额外5 - HT3结合位点的证据。
Br J Pharmacol. 1995 Sep;116(2):1781-8. doi: 10.1111/j.1476-5381.1995.tb16663.x.

引用本文的文献

1
Regulated export of a secretory protein from the ER of the hepatocyte: a specific binding site retaining C-reactive protein within the ER is downregulated during the acute phase response.肝细胞内质网中分泌蛋白的调控性输出:急性期反应期间,内质网内保留C反应蛋白的特异性结合位点下调。
J Cell Biol. 1992 Jul;118(2):253-65. doi: 10.1083/jcb.118.2.253.
2
Stable expression of mammalian type A gamma-aminobutyric acid receptors in mouse cells: demonstration of functional assembly of benzodiazepine-responsive sites.哺乳动物A型γ-氨基丁酸受体在小鼠细胞中的稳定表达:苯二氮䓬反应位点功能组装的证明
Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6378-82. doi: 10.1073/pnas.89.14.6378.

本文引用的文献

1
A method for determining the sedimentation behavior of enzymes: application to protein mixtures.一种测定酶沉降行为的方法:应用于蛋白质混合物
J Biol Chem. 1961 May;236:1372-9.
2
Molecular size of muscarinic acetylcholine receptors of rat brain.大鼠脑毒蕈碱型乙酰胆碱受体的分子大小
FEBS Lett. 1980 Apr 21;113(1):68-72. doi: 10.1016/0014-5793(80)80497-2.
3
The nicotinic cholinergic receptor: correlation of molecular structure with functional properties.烟碱型胆碱能受体:分子结构与功能特性的相关性
Annu Rev Biochem. 1982;51:491-530. doi: 10.1146/annurev.bi.51.070182.002423.
4
Primary structures of beta- and delta-subunit precursors of Torpedo californica acetylcholine receptor deduced from cDNA sequences.从cDNA序列推导的加州电鳐乙酰胆碱受体β和δ亚基前体的一级结构。
Nature. 1983 Jan 20;301(5897):251-5. doi: 10.1038/301251a0.
5
Purification by affinity chromatography of the glycine receptor of rat spinal cord.大鼠脊髓甘氨酸受体的亲和层析纯化
J Biol Chem. 1982 Aug 25;257(16):9389-93.
6
Purification and characterization of a nicotinic acetylcholine receptor from chick brain.鸡脑烟碱型乙酰胆碱受体的纯化与特性分析
Biochemistry. 1986 Apr 22;25(8):2082-93. doi: 10.1021/bi00356a037.
7
Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.利用放射性配体结合法鉴定大鼠脑中5-羟色胺3型受体及其分布
Nature. 1987;330(6150):746-8. doi: 10.1038/330746a0.
8
Characterisation of 5-HT3 recognition sites in membranes of NG 108-15 neuroblastoma-glioma cells with [3H]ICS 205-930.用[³H]ICS 205-930对NG 108-15神经母细胞瘤-胶质瘤细胞膜中5-HT3识别位点的表征。
Naunyn Schmiedebergs Arch Pharmacol. 1988 May;337(5):493-9. doi: 10.1007/BF00182721.
9
[3H]quaternised ICS 205-930 labels 5-HT3 receptor binding sites in rat brain.[3H]季铵化ICS 205 - 930标记大鼠脑中的5 - HT3受体结合位点。
Eur J Pharmacol. 1988 May 10;149(3):397-8. doi: 10.1016/0014-2999(88)90677-2.
10
[3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes.[3H]喹哌嗪标记大鼠皮层膜中的5-羟色胺3(5-HT3)识别位点。
Eur J Pharmacol. 1988 Mar 29;148(2):297-9. doi: 10.1016/0014-2999(88)90579-1.